Dr. Abato provides expert witness services in connection with Hatch-Waxman type ANDA and patent infringement litigation in the area of pharmaceutical technology. Dr Abato has been deposed twice, sat in and advised counsel on two other depositions, was involved with one pretrial preparation and has testified in a federal court.
His services as an expert witness have been retained by a major Generic Pharmaceutical Company, where he was deposed and participated in pretrial preparation. Dr Abato has also served as an expert witness for a Nutraceutical Company where he gave testimony at trial regarding a patented formulation.
Dr Abato has been involved in all aspects of drug research and development from formulation development, synthesis/purification, in-vitro, in-vivo (efficacy and pharmacokinetics), dosing routes, and the management of CROs to support pre-clinical testing.
Presently, Dr Abato is consulting for the Bill and Melinda Gates Medical Research Institute in the development of new drug combinations to be used in clinical trials against resistant TB infections.
A Ph. D. Medicinal Chemist with over 25 years of experience in the discovery and development of novel human therapeutics in the areas of anti-infective, anti-inflammatory and neurodegenerative diseases. He contributed to the development of NUZYRA, a new antibiotic, approved by the FDA in 2018.
Dr Abato was awarded the prestigious Heroes of Chemistry award by the American Chemical Society in 2019 for his work on NUZYRA.